Clinical spectrum and survival outcomes of malignancies in pediatric patients with inborn errors of immunity.
In a single-center retrospective cohort of 1,668 pediatric patients with inborn errors of immunity, 67 developed malignancy—usually advanced-stage lymphoma and often before IEI recognition—with selected clinical factors associated with survival and no reported relapse among 12 allogeneic HSCT recipients.
Open original publication →What the AI sees
In a single-center retrospective cohort of 1,668 pediatric patients with inborn errors of immunity, 67 developed malignancy—usually advanced-stage lymphoma and often before IEI recognition—with selected clinical factors associated with survival and no reported relapse among 12 allogeneic HSCT recipients.
Research significance
The evidence shows frequent malignancy-first presentation, advanced disease, prognostic associations, and no observed post-transplant relapse in a small selected HSCT subgroup; it supports the inference—not proof—that earlier immunologic evaluation and risk-adapted consideration of HSCT could improve management for some children with IEI-associated cancer.
Source abstract
BACKGROUND: Inborn errors of immunity (IEI) predispose patients to malignancy, particularly lymphoma, but data on diagnostic sequence and outcomes are limited. METHODS: We retrospectively analyzed IEI-associated malignancies diagnosed at a single center between January 2004 and December 2025. RESULTS: Among 1,668 patients with IEI, 67 (4.0%) developed malignancy. Median ages at IEI and malignancy diagnosis were 8 and 10 years, respectively. Malignancy-first presentation occurred in 45 patients (67%), especially adolescents, and was associated with advanced-stage disease (p = 0.007). Lymphoid malignancies accounted for 90% of cases; non-Hodgkin lymphoma and Hodgkin lymphoma comprised 54% and 36%, respectively, and 84.7% presented with stage III-IV disease. Median event-free and overall survival were 66 and 155 months, respectively. In a clinically selected multivariable Cox model, NHL, solid/plasma cell tumors, older age at malignancy diagnosis, and DNA repair defect status were associated with worse OS. Twelve patients underwent allogeneic HSCT; one died early, and no post-transplant relapses occurred. CONCLUSION: Early immunologic evaluation and timely, individualized consideration of HSCT may support optimized management in children and adolescents, in whom cancer may be the first manifestation of IEI.